Full Text View
Tabular View
No Study Results Posted
Related Studies
Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC) (XP+Sorafenib)
This study has been completed.
Study NCT00565370   Information provided by Asan Medical Center

First Received on November 28, 2007.   Last Updated on January 16, 2013   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Advanced Gastric Cancer
Additional conditions recognized in this trial
Stomach Neoplasms
More general conditions related to this trial
Digestive System Diseases
Digestive System Neoplasms
Gastrointestinal Diseases
Gastrointestinal Neoplasms
Neoplasms
Neoplasms by Site
Stomach Diseases
Interventions listed in this trial
Capecitabine, Cisplatin, Sorafenib
Additional drug interventions recognized in this trial
Capecitabine
Cisplatin
Fluorouracil
Sorafenib
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
Asan Medical Center


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services